Absci Sales Fall 54 Percent

Absci (NASDAQ:ABSI), a biotechnology company focused on generative AI-driven drug discovery, issued its second quarter fiscal 2025 earnings on August 12, 2025. The release highlighted a steep revenue decline and wider losses, overshadowing operational progress in the pipeline and platform partnerships. GAAP revenue was $0.6 million, well below the $1.26 million GAAP analyst estimate. Net loss per share (GAAP) was $0.24, compared to a GAAP net loss per share of $0.22 in Q2 2024. Research and development spending (GAAP) increased notably compared to Q2 2024. In response to these trends, Absci raised approximately $64 million in gross proceeds in July 2025, extending its projected cash runway into the first half of 2028. Overall, the quarter showcased advancements in research and partnerships, but also underscored significant pressure on near-term revenue and growing expenses. Source: Analyst estimates for the quarter provided by FactSet. Absci is built around its “Integrated Drug Creation Platform,” marrying generative artificial intelligence, synthetic biology, and wet-lab validation. In plain terms, the platform uses advanced algorithms to design and quickly test new therapeutic antibodies, drastically speeding up a process that traditionally takes years. The company says its technology can design and screen billions of antibody candidates in weeks.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool